Design of the Optimal Trial of Combination Therapy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Patients who take levothyroxine monotherapy to treat hypothyroidism frequently experience residual symptoms despite TSH testing at target levels. Trials have been conducted to evaluate the potential benefit of combination therapy with levothyroxine and liothyronine, though results have not consistently demonstrated benefit. In addition to randomization, placebo-control, and masking, four additional design choices to consider include the study population, dosing strategy for levothyroxine and liothyronine, primary and secondary outcome selection, and statistical power. A thoughtful design that considers these features will increase the likelihood that a combination trial will be considered definitive and finally resolve the important question of whether combination therapy with levothyroxine and liothyronine is a better thyroid replacement strategy than levothyroxine monotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Self-citationCognition assessment using the NIH Toolbox
Weintraub, S., Dikmen, S. S., Heaton, R. K., Tulsky, D. S., Zelazo, P. D., Bauer, P. J., Carlozzi, N. E., Slotkin, J., Blitz, D., Wallner-Allen, K., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182872ded · Cited by 1,287 · cited 1×
“An example is the fluid cognition composite score of the NIH Toolbox cognition battery (14).”
BackgroundSaravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514
An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231 · cited 1×
“Which efficacy outcomes will change clinical practice? The primary reason that patients pursue combination therapy is to ameliorate symptoms of hypothyroidism that can be found in a simple internet search (6).”
BackgroundSelf-citationValidity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO
Watt, T., Hegedüs, L., Groenvold, M., Bjorner, J. B., Rasmussen, Å. K., Bonnema, S. J., & Feldt-Rasmussen, U. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0521 · Cited by 210
Is a Normal TSH Synonymous With “Euthyroidism” in Levothyroxine Monotherapy?
Peterson, S. J., McAninch, E. A., & Bianco, A. C. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2660 · Cited by 182 · cited 1×
“In addition, patients who are taking LT4 therapy have higher free T4 and lower T3 levels than euthyroid counterparts who are not taking LT4 (4).”
BackgroundWatt, T., Cramon, P., Hegedüs, L., Bjorner, J. B., Bonnema, S. J., Rasmussen, Å. K., Feldt-Rasmussen, U., & Groenvold, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1322 · Cited by 152
Development of a Short Version of the Thyroid-Related Patient-Reported Outcome ThyPRO
Watt, T., Bjorner, J. B., Groenvold, M., Cramon, P., Winther, K. H., Hegedüs, L., Bonnema, S. J., Rasmussen, Å. K., Ware, J. E., & Feldt-Rasmussen, U. (2015) · Thyroid · doi:10.1089/thy.2015.0209 · Cited by 132
Watt, T., Bjorner, J. B., Groenvold, M., Rasmussen, Å. K., Bonnema, S. J., Hegedüs, L., & Feldt-Rasmussen, U. (2009) · Quality of Life Research · doi:10.1007/s11136-009-9460-8 · Cited by 112
Wong, C. K. H., Lang, B. H. H., & Lam, C. L. K. (2016) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2016.03.006 · Cited by 78 · cited 1×
“Multiple questionnaires exist, though in a systematic review of quality of thyroid-specific health-related quality-of-life instruments, the Thyroid-Related Quality of Life PatientReported Outcome (ThyPRO) questionnaire was recommended for patients with hypothyroidism (7).”
Background
Cited by
Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75
Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism
Idrees, T., Palmer, S., Maciel, R. M. B., & Bianco, A. C. (2020) · Thyroid® · doi:10.1089/thy.2020.0153 · Cited by 58
Riis, K. R., Larsen, C. B., & Bonnema, S. J. (2024) · Thyroid® · doi:10.1089/thy.2023.0649 · Cited by 10
“11 14 It is debated whether this is caused by insuf fi cient amounts of T3 in the tissues due to an inadequate conversion of thyroxine (T4) by deiodinases.”
Premawardhana, L. D., Taylor, P. N., Okosieme, O. E., Adlan, M. A., Obuobie, E. K., & Dayan, C. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1282608 · Cited by 6
“…question of the ef fi cacy of LT3 + LT4 in this situation: (1) Selection of trial subjects (a) Presence of symptoms and threshold for recruitment The primary outcome of any RCT of LT3 + LT4 in hypothyroidism should be their effect on symptoms and QoL, as recommended by expert bodies (22, 23).”
BackgroundResult
Metadata
- Authors
- Cappola, A. R.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-03
- Volume
- 11
- Pages
- 168-168
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3014830386
- Cited by
- 6
- References
- 13
- FWCI
- 0.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design of the Optimal Trial of Combination Therapy. https://app.cochat.ai/papers/10.3389/fendo.2020.00168
- The paper
- Cappola, A. R. (2020). Design of the Optimal Trial of Combination Therapy. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2020.00168
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.